Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY06006 vs EU Prolia in postmenopausal osteoporosis
jRCT2031220657Phase 3Recruiting
- Sponsor
- Boan Biotech
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of CMAB807 in postmenopausal osteoporosis (2 arms), sponsored by Boan Biotech. Primary endpoint: % change from baseline in lumbar spine BMD at Month 12. Started May 2023; status: recruiting.
02
Drugs
CMAB807
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on jRCT2031220657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220657.